Today: 8 June 2026
Browse Category

NASDAQ:PLRZ 2 December 2025 - 8 December 2025

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon shares surged over 100% to the mid-teens on December 4, 2025, with volume topping 26 million after announcing a manufacturing milestone for its PL‑14 Allergy Blocker and promising preclinical data for its naloxone hydrogel. The stock saw heavy volatility and mixed analyst signals, with “Strong Sell” ratings alongside momentum-driven “Buy” calls. The Israel-based biotech has no approved products.
4 December 2025
···
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. shares surged to $13–15 by early afternoon December 4, more than doubling from the previous close of $7.09, after hitting intraday highs above $18. The rally followed news of a manufacturing milestone for its PL‑14 allergy nasal spray and new preclinical data showing improved mucoadhesion for its naloxone hydrogel. Polyrizon, based in Israel, has no approved products and reported a 2024 net loss of about $1.5 million.
4 December 2025
··
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd shares surged 130% on December 2 after announcing a manufacturing upscaling milestone for its PL‑14 nasal allergy blocker. The stock closed at $7.33, up from $3.16, with trading volume near 150 million shares. The Israeli biotech, which has no approved products or revenue, now trades around $6 pre-market. Polyrizon develops intranasal hydrogel sprays and remains in the pre-commercial stage.
3 December 2025
··
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon Ltd. shares surged 131.96% on December 2, 2025, closing at $7.33 after announcing a key manufacturing milestone for its PL-14 nasal spray. Intraday trading saw prices swing between $5.85 and $8.36 on volume over 148 million shares. The Israeli biotech, still pre-commercial with no approved products or revenue, now holds a market cap near $14–15 million.
2 December 2025
·

Stock Market Today

  • S&P 500 and Nasdaq Rise as Tech and Chip Stocks Rebound
    June 8, 2026, 5:38 PM EDT. The Nasdaq and chipmaker stocks led gains in U.S. markets, as investors capitalized on bargain opportunities after a recent sharp selloff. The rebound followed easing geopolitical tensions between Iran and Israel, boosting market sentiment. This recovery highlights renewed confidence in the technology and semiconductor sectors, which had suffered amid earlier volatility.

Latest articles

UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

8 June 2026
UiPath shares dipped 0.7% to $11.17 despite a strong quarter and raised outlook, as investors focused on slow annual recurring revenue growth and analyst caution, with Morgan Stanley cutting its price target and BofA maintaining Underperform, citing the need for clearer evidence that AI-driven automation can accelerate durable contract revenue.
IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

8 June 2026
IREN surged 9% to $59.19 as investors returned to crypto and AI infrastructure stocks after last week’s selloff, driven by a $3.65 billion investment-grade GPU financing to support its Microsoft AI cloud contract and news of a planned 800MW data-center in Australia, but future gains hinge on execution, contract delivery, and bitcoin price stability.
SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

8 June 2026
SmartKem shares soared as much as 150% to $1.135 before settling at $0.84 after SRx Health Solutions disclosed a 4.99% stake and purchase of convertible preferred securities, injecting new investor interest as SmartKem faces a Sept. 1 Nasdaq delisting risk for trading below $1 and warns of “substantial doubt” about its ability to continue as a going concern.
Texxon Trading Halted Six Times as NPT Jumps 284% in New York

Texxon Trading Halted Six Times as NPT Jumps 284% in New York

8 June 2026
Texxon shares soared 283.7% to $4.95, briefly topping $12 before closing just below their $5 IPO price, with trading paused six times for volatility and volume over six times shares outstanding; the company warned that similar IPOs had seen sharp, non-fundamental price swings, highlighting ongoing risk for investors.
Social Security Payments Land This Week—June 10 Recipients

Social Security Payments Land This Week—June 10 Recipients

8 June 2026
Social Security’s retirement trust fund could force a 24% benefit cut by 2032, slashing average monthly payments by about $500 for retirees, according to the Committee for a Responsible Federal Budget, as the official trustees project full benefits only until 2033 and continuing income covering just 77% thereafter.
Go toTop